DGAP-News

MOLOGEN AG: MOLOGEN AG: Extension of TEACH study based on supportive first study results

DGAP-News: MOLOGEN AG / Key word(s): Study/Conference
MOLOGEN AG: MOLOGEN AG: Extension of TEACH study based on supportive first
study results

14.03.2016 / 08:30
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PRESS RELEASE N 4/ 2016 of 03/14/2016

MOLOGEN AG: Extension of TEACH study based on supportive first study
results

Berlin, 14 March 2016 - The biotech company MOLOGEN AG (ISIN DE0006637200;
Frankfurt Stock Exchange Prime Standard: MGN) announced today that the
TEACH study with its immunomodulatory lefitolimod (MGN1703) in HIV patients
will be extended as a result of the broad immune system activation induced
by the drug. This was shown by the increased activation of various immune
markers. In conclusion and consistent with the underlying hypothesis,
lefitolimod (MGN1703) dosing led to the activation of plasmacytoid
dendritic cells (pDC), natural killer cells (NK) and T cells in HIV
patients during the antiretroviral therapy (ART). Thus, lefitolimod
(MGN1703) could serve as a robust immune stimulator or "kill" agent in
"kick and kill" HIV eradication trials. Initially patients received one
month of treatment and now the protocol has been amended to give a longer
treatment of six months with lefitolimod (MGN1703) in some more patients.
Recruitment of these patients is expected in the next few weeks and final
study results will now be available in the first half of 2017.

"We are excitedly following the developments of lefitolimod in HIV. The
strong enhancement of antiviral immune responses observed after a short
course of treatment gives us the rationale to extend the study, also at the
light of the very good safety profile of the drug," said Ole Schmeltz
Søgaard, MD, PhD, Associate Professor at the Aarhus University Hospital,
Dept. of Infectious Diseases, Aarhus, Denmark.

"We have always believed that the immunomodulator lefitolimod could also
play a role in infective diseases. We look forward to the results in HIV
patients treated for a longer period of time with great interest," said Dr.
Alfredo Zurlo, Chief Medical Officer of MOLOGEN AG.

The aim of the TEACH study is to see if the immunotherapy with MGN1703 can
activate the innate and adaptive immune system in HIV patients, to enhance
killing of the HIV infected cells.

Initial results of the first patients treated in the trial will be
presented at the Keystone HIV Symposia (Keystone Symposia on molecular and